Silexion reports new preclinical data: up to 97% cancer cell inhibition, first evidence against KRAS Q61H mutation

Silexion Therapeutics Corp

SIL204 achieved up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutation (previously untested).
Dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutation at nanomolar concentrations.
Nearly 90% inhibition in colorectal cancer cells with KRAS G12D mutation, extending efficacy beyond pancreatic cancer.
Data covers three major KRAS-driven cancers: pancreatic, colorectal, and lung; on track for Phase 2/3 trial in Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.